SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration....

Full description

Saved in:
Bibliographic Details
Main Authors Nivorozhkin, Alex, Landrau, Nelson
Format Patent
LanguageEnglish
Published 20.08.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
Bibliography:Application Number: US202016868444